NCT04854759 (COV-PREVENT) is a Phase 3 clinical trial of Amantadine Hydrochloride in COVID-19, sponsored by Independent Public Clinical Hospital No. 4 in Lublin.

Who is sponsoring NCT04854759?

NCT04854759 is sponsored by Independent Public Clinical Hospital No. 4 in Lublin.

What drugs are being tested in NCT04854759?

Interventions in NCT04854759: Amantadine Hydrochloride, Placebo.

What condition does NCT04854759 study?

NCT04854759 studies COVID-19, SARS-CoV-2.

Is NCT04854759 still recruiting?

NCT04854759 is currently status unknown. Last updated 13 August 2021.

Last reviewed 2021-08-13 · How we verify

NCT04854759: COV-PREVENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms

Status unknown Phase 3 Last updated 13 August 2021

What this trial tests

Phase 3 trial testing Amantadine Hydrochloride in COVID-19 in 200 participants. Status unknown.

Timeline

15 March 2021

Primary endpoint
31 March 2022

31 May 2022

Quick facts

Lead sponsor	Independent Public Clinical Hospital No. 4 in Lublin
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	15 March 2021
Primary completion	31 March 2022
Estimated completion	31 May 2022
Sites	8 locations across Poland

Drugs / interventions tested

Amantadine Hydrochloride — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →
SARS-CoV-2 — all drugs for SARS-CoV-2 →

Sponsor

Independent Public Clinical Hospital No. 4 in Lublin

Who can join

18 and older, any sex, with COVID-19 or SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus. Multicenter randomized, double-blind, placebo-controlled, non-commercial clinical trial

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Small molecules in the treatment of COVID-19.
Lei S, Chen X, Wu J, Duan X, et al · · 2022 · cited 74× · PMID 36464706 · DOI 10.1038/s41392-022-01249-8
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1
Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.
Toft-Bertelsen TL, Jeppesen MG, Tzortzini E, Xue K, et al · · 2021 · cited 42× · PMID 34853399 · DOI 10.1038/s42003-021-02866-9
The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design.
Rejdak K, Fiedor P, Bonek R, Goch A, et al · · 2022 · cited 12× · PMID 35390511 · DOI 10.1016/j.cct.2022.106755
Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?
Esposito R, Mirra D, Sportiello L, Spaziano G, et al · · 2022 · cited 8× · PMID 36359334 · DOI 10.3390/biomedicines10112815
Anti-SARS-CoV-2 Activity of Adamantanes In Vitro and in Animal Models of Infection.
Lim SY, Guo Z, Liu P, McKay LGA, et al · · 2022 · cited 6× · PMID 37274537 · DOI 10.3390/covid2110111
Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study.
Barczyk A, Czajkowska-Malinowska M, Farnik M, Barczyk M, et al · · 2023 · cited 6× · PMID 36931576 · DOI 10.1016/j.rmed.2023.107198

Verify or expand the search:

Other trials of Amantadine Hydrochloride

Trials testing the same drug.

NCT04273737 — Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy · Phase 4 · terminated

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04854759 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Independent Public Clinical Hospital No. 4 in Lublin
Last refreshed: 13 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04854759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing